New Hypertension Drug Data Will Be Presented in October
Researchers will share findings on how a novel therapy impacts patients with dysregulated aldosterone levels.
Updated on Oct. 1, 2026 in Heart Disease
Live Poll
Do you trust that new medical innovations are improving the management of chronic high blood pressure?
Mineralys Therapeutics will present five abstracts regarding its investigative drug, lorundrostat, at the American Heart Association Hypertension Scientific Sessions 2026. The presentation, scheduled for October 7-11, 2026, focuses on clinical trial outcomes for managing hypertension.
Why it matters
Hypertension is a significant health burden, contributing to over 685,000 deaths in the United States in 2022. Targeting the biological pathways involved in high blood pressure remains a key area of study for improving long-term cardiovascular health.
Data from the global Phase 3 Launch-HTN trial and the Phase 2 Explore-OSA trial will be shared, highlighting a 40-70% reduction in plasma aldosterone concentration. These findings assess the efficacy of 50 mg daily doses in patients compared to those receiving a placebo.
The players
Mineralys Therapeutics
A clinical-stage biopharmaceutical company focused on developing therapies for hypertension and aldosterone-related conditions.
The details
Lorundrostat is designed to inhibit aldosterone synthase, an enzyme that regulates aldosterone production in the body. The drug demonstrates 374-fold selectivity for aldosterone-synthase inhibition over cortisol-synthase inhibition in vitro. With an observed half-life of 10-12 hours, the medication is intended to address the approximately 30% of hypertensive patients who have dysregulated aldosterone levels.
Timeline
October 7-11, 2026: AHA Hypertension Scientific Sessions in Arlington, VA.
October 8, 2026: Oral presentation of Explore-OSA trial results.
October 9, 2026: Poster presentations regarding Launch-HTN and other studies.
Health Landscape
The presentation of study data at the American Heart Association Hypertension Scientific Sessions serves as a major forum for evaluating the latest advancements in blood pressure management. This data release aligns with the ongoing clinical investigation into targeted therapies for aldosterone-related hypertension.
If you are managing hypertension, the findings from these clinical trials provide insight into how new medications may one day target the underlying hormonal drivers of your condition. It is worth discussing with your doctor how emerging research into aldosterone-related blood pressure issues could affect your care strategy.
The takeaway
Understanding the role of aldosterone in blood pressure regulation can help you have more informed conversations with your medical team. Track your blood pressure readings regularly and discuss with your physician whether your current treatment plan addresses your specific cardiovascular risk factors.
Further reading
For more on evolving treatment approaches, see our coverage in Heart Disease.
More information
Learn more about the company's research pipeline on the Mineralys Therapeutics corporate website.
Live Poll
Do you trust that new medical innovations are improving the management of chronic high blood pressure?
